Exiqon's Q1 Revenues Decline 13 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Exiqon today reported that its first-quarter revenues fell 13 percent year over year on weak sales in North America.

The Denmark-based genomics tools and molecular diagnostics developer reported total revenues of DKK 24 million ($4.2 million) for the three months ended March 31, compared to DKK 27.6 million for the first quarter of 2011. It said that organic sales growth for research products was 25 percent in Europe, offset by a 33 percent decline in North America, where it said that it is implementing a new sales strategy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: statistical approach to examine intra-tumor heterogeneity, new genetic condition called otulipenia, and more.

Blood tests looking for biomarker changes could catch mental illnesses earlier, Newsweek reports.

DNA testing offers Korean adoptees a way to find their birth parents that sidesteps bureaucratic red tape, according to the New York Times.

A National Institutes of Health researcher has filed an Equal Employment Opportunity complaint against the agency, the Washington Post reports.